TAKE Solutions announced today that its worldwide business in regulatory document management and electronic submissions software arena is making quick inroads in the Indian market. The addition of these new clients to TAKE Solutions’ globally renowned PharmaReady suite, makes this product very well entrenched in the Indian market. Amongst others, key customers in India are Ajanta Pharma, Alembic Ltd., Alkem, Dabur, Emcure Pharmaceuticals, Marksans Pharma and Serum Institute. With esubmissions becoming mandatory in many of the countries in the West, more and more Pharma companies in India are realizing the need to update their processes and procedures to the eSubmissions platform. With a 100% implementation and submissions success rate, PharmaReady is being put to constant use by customers in · 12 countries · across 4 continents
The PharmaReady suite of software distinguishes itself from the marketplace by being relevant to a wide range of global life sciences customers and prospects. This includes branded and generic bio-pharmaceutical companies in various stages of their research and application process as they seek approval from global regulatory agencies. This success of the ParmaReady Suite can be attributed to 3 key factors:
Unlike many of its competitors, TAKE Solutions has near shore support centers located in Chennai, India for the Asia Pacific customer base that makes it very convenient for users located in this part of the world. TAKE’s offices in North America serve as the support centers for the North American and European customer base. Talking about the company’s growth Mr. L. Ramesh, Vice President – Sales: Life Sciences – Asia Pacific & Emerging Markets, TAKE Solutions Ltd. said, “We continuously strive to add value and bring the significance and relevance of global regulatory standards to the life sciences customer base, acting as a key liaison and a thought leader in this space”. Sourced From: Adfactors Public Relations Pvt Ltd |
|
|
|
| View Comments | Post Comments |
| Headlines from Web18 |




















